Search - tctmd.com

Displaying 241 - 260 of 415

Sort: Relevancy | Date

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

News Daily News

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

November 01, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

AMBULATE: Venous Closure Device Pays Off After Catheter Ablation

News Daily News

AMBULATE: Venous Closure Device Pays Off After Catheter Ablation

October 31, 2019

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

News Daily News

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Michael O'Riordan

October 29, 2019

Anticoagulant Type May Influence Fracture Risk in A-fib Patients

News Daily News

Anticoagulant Type May Influence Fracture Risk in A-fib Patients

October 21, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Endurance Training and A-fib: Relationship Differs by Sex

News Daily News

Endurance Training and A-fib: Relationship Differs by Sex

August 29, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

News Daily News

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

August 19, 2019

Meta-analysis Supports Surgical LAA Occlusion During Cardiac Surgery, but Flaws Found

News Daily News

Meta-analysis Supports Surgical LAA Occlusion During Cardiac Surgery, but Flaws Found

August 16, 2019

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

News Features

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Marcus A. Banks

August 15, 2019

Higher Risk of Atrial Fibrillation in Retired Football Players

News Daily News

Higher Risk of Atrial Fibrillation in Retired Football Players

Michael O'Riordan

July 25, 2019

Infection During CV Hospital Stays Tied to Higher Costs, Greater Death Risk

News Daily News

Infection During CV Hospital Stays Tied to Higher Costs, Greater Death Risk

Marcus A. Banks

July 24, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.